You just read:

Boston Biomedical Announces Clinical Data on First-in-Class Investigational Cancer Stem Cell Pathway Inhibitors Napabucasin and Amcasertib in Multiple Cancer Types at ASCO 2016

News provided by

Boston Biomedical Pharma, Inc.

May 18, 2016, 17:42 ET